
via The Scripps Research Institute
Findings Point to Potential New Use of an Existing Drug
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Go deeper with Bing News on:
Multiple Sclerosis
- Why BioNTech's Multiple Sclerosis Vaccine Could Be a Game Changeron January 23, 2021 at 3:13 am
Follow @keithspeights Multiple therapies are on the market today for treating multiple sclerosis (MS). But what about a vaccine for MS? There isn't one available yet. However, German biotech BioNTech ...
- Multiple Sclerosis Therapeutics Market Future Scope, Opportunities with Strategic Growth and Top Playerson January 22, 2021 at 2:11 am
The report offers overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts. The market studied ...
- Research suggests development of antiviral therapies to treat multiple sclerosison January 20, 2021 at 4:00 pm
Scientists have uncovered new clues implicating a type of herpes virus as the cause of a central nervous system disease in monkeys that's similar to multiple sclerosis in people. By linking two ...
- Hematopoietic stem cell transplants may provide long-term benefit for people with multiple sclerosison January 20, 2021 at 1:03 pm
A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people ...
- Could a Head Injury Raise Your Teen’s Multiple Sclerosis Risk?on January 20, 2021 at 1:03 pm
Studies have linked head injuries and MS. Learn about the connection and find out what you can do to protect your child.
Go deeper with Google Headlines on:
Multiple Sclerosis
Go deeper with Bing News on:
MS
- Man smuggling drugs into South MS prison was paid with money and sex, authorities sayon January 25, 2021 at 4:45 am
A corrections officer spotted the suspect throwing items over the razor-wire fences surrounding the prison earlier this month. Here are the details.
- IPL 2021 | MS Dhoni Thinks About Building Team For a Particular Season: Gautam Gambhir Points Out Difference Between CSK and RCBon January 25, 2021 at 1:56 am
Former India opener Gautam Gambhir gave his opinion on Chennai Super Kings’ policy of releasing players like Piyush Chawla and Kedar Jadhav. In IPL 2020, Chennai failed to qualify for the play-offs ...
- IPL 2021: MS Dhoni would have given Kedar Jadhav another season at CSK if not for price tag - Gautam Gambhiron January 25, 2021 at 12:08 am
Former Kolkata Knight Riders captain Gautam Gambhir heaped praise on MS Dhoni and Chennai Super Kings' retention strategy, defending the former champions' move to let go of only 5 players before the ...
- MS Dhoni’s New Look Ahead of IPL 14 is Winning Hearts | SEE PICSon January 24, 2021 at 11:40 pm
Former India skipper MS Dhoni’s new look is impressing fans again. Pictures of Dhoni’s new-look, where he is clean-shaven surfaced on social space on Sunday and since has gone viral. In the new ...
- 'This is MS Dhoni's specialty': Gautam Gambhir explains why CSK had the 'right strategy' in retaining key playerson January 24, 2021 at 7:54 pm
While CSK released the likes of Kedar Jadhav, Piyush Chawla, Harbhajan Singh, they kept CSK's core players Suresh Raina, Ambati Rayudu, Faf du Plessis, and Dwayne Bravo.